News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
ArQule, Inc. Provides Clinical Update on ARQ 197
October 5, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WOBURN, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
Neuropsychiatric disorders
Otsuka, Lundbeck’s PTSD Bid for Rexulti Hits Speedbump as FDA Questions Efficacy
July 17, 2025
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH EVOTEC
Webinar: Pharma Industry in Crisis
July 16, 2025
·
1 min read
·
BioSpace Insights
Rare diseases
AstraZeneca’s Amyloidosis Asset Stumbles in Late-Stage Trials
July 16, 2025
·
1 min read
·
Dan Samorodnitsky
Infectious disease
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25
July 15, 2025
·
4 min read
·
Tristan Manalac
